Radically more accurate cancer prognostics using AI

DoMore Diagnostics is a precision oncology company developing advanced AI-based diagnostic tools that guide individualized cancer treatment decisions. The company’s technology analyzes complex tumor biology to predict how patients will respond to specific therapies. By moving beyond traditional staging and biomarker-based approaches, DoMore enables clinicians to tailor treatment plans to each patient’s underlying biology.

The platform aims to improve survival rates, reduce unnecessary treatment, and lower healthcare costs by identifying which patients will truly benefit from chemotherapy and other interventions. DoMore’s solutions are clinically validated and designed for seamless integration into existing hospital workflows, making precision medicine practical at scale.

Operating at the intersection of biotechnology, data science, and clinical oncology, DoMore Diagnostics is positioned to redefine how treatment decisions are made in cancer care.